NCT01661166View on ClinicalTrials.gov

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 15, 2013

Study Completion Date

April 15, 2013

Conditions
Prostate Adenocarcinoma
Interventions
DRUG

Fesoterodine

4 mg

DRUG

Placebo oral tablet

Placebo

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01661166 - A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy | Biotech Hunter | Biotech Hunter